Close Menu

NEW YORK (GenomeWeb) — Pacific Biosciences announced this week that it has reached the final developmental milestone of its commercialization and licensing agreement with Roche. The agreement, originally announced in September, entitles Roche to commercialize and sell clinical diagnostics products developed by PacBio based on the company's Single Molecule, Real Time technology. With the final milestone achieved, Roche has paid PacBio an additional $20 million.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Wall Street Journal reports that Russia's announcement of a coronavirus vaccine approval was met with concern as safety testing has not yet been completed.

New Scientist writes there aren't much data available on the accuracy of the two rapid COVID-19 tests the UK plans to roll out.

In PNAS this week: downstream effect of oncoprotein fusion, epigenetic changes influence tRNAs in colon cancer, and more.

Nature News reports that recent proposed changes to the US National Science Foundation have raised concerns about a shift away from the agency's focus on basic research.